Search 

Robin Medical, Inc., has developed and commercialized a wide range of medical devices since its formation in 1997. The ultimate goal of its newest cryopreservation technology is to collect biopsy tissue samples that retain the cells’ viability, the in-vivo biochemical profile, and the tissue ultrastructure by using differential freezing profile that keeps part of the sample frozen (for biomarker analysis) and part unfrozen (for histology analysis). The cryogenic apparatus is either built into a cryobiopsy needle (CyroBx™)  to enable in-situ freezing of the tissue, or in a disposable sample holder (the CryoTray™) that maintains differential cryo temperature profile of samples acquired by any biopsy device.

The CryoBx™ will initially address the market of breast vacuum-assisted biopsy (VAB), estimated at $300 million, as a competitive VAB device with tissue cryopreservation. We then plan to address the much larger market of biopsy devices for internal organs that require thinner biopsy needles. In parallel, the company plans to complete the development of the CryoTray™tissue holder, to conduct clinical studies and to release it to market for use in any biopsy procedure.  A pending U.S. patent application for the cryogenic biopsy device and method awaits USPTO Office Action; a provision patent application covering the innovation of the CryoTray™ has been recently filed. Robin Medical has raised $15 million since its formation in 1997. The company looks for phase I investment of $1.5 million and intends to to apply for an SBIR Phase IIB (bridge) grant. The raised funds will be used to continue the development and clinical testing of the devices and to commercialize the biopsy cryopreservation line of products.

Synergys Biotherapeutics is a privately held antibody therapeutics company developing multifunctional anti-vasculogenic antibody therapeutics for cancer and other angiogenesis-related diseases of significant unmet medical needs. The Company focuses on in-licensing early stage candidates from external sources for additional development in-house as well as through building collaboration and partnering with larger pharma and biotech organizations. The Company’s current preclinical programs include Anti-EGFR-ATAP, an antibody fusion molecule being developed for Triple Negative Breast Cancer and other EGFR+ malignancies, as well as a bi-targeted, bifunctional “first-in-class” fully human Anti-Ang-1/2 antibody for various cancers.   Synergys’ management and the members of its scientific and business advisory boards are veterans of biotech business having more than 20 years of average expertise and experience in cancer drug development.